Radnet takes majority stake in Heart & Lung Imaging

RadNet, a US-based medical imaging specialist, has acquired a 75% majority stake in Heart & Lung Imaging Limited (HLH), a UK-based teleradiology network focused on detecting and diagnosing lung and cardiovascular diseases. This move is part of RadNet's strategy to enhance its capabilities in early cancer detection and develop solutions that combine artificial intelligence (AI) with specialized medical expertise. Through this acquisition, RadNet expands its presence in the UK and positions itself in a market with significant growth prospects, driven in part by the National Health Service's (NHS) Targeted Lung Health Check (TLHC) program. This lung cancer screening program, targeting high-risk populations aged 55-74 with a history of smoking, is expected to generate over one million lung scans per year in England. By integrating HLH, RadNet can leverage its new partner's image reading and interpretation capabilities, combined with the AI technologies developed by its Dutch subsidiary Aidence, which specializes in automated lung nodule detection. The acquisition also aims to accelerate the deployment of large-scale population screening programs, a strategic segment for RadNet. By combining AI tools with the expertise of specialized radiologists, the company seeks to improve diagnostic accuracy, reduce unnecessary patient recalls, and optimize healthcare costs. Beyond the UK, this platform could serve as a model for developing similar programs in the US and other international markets.